×
About 3,100 results

ALLMedicine™ IgA Nephropathy Center

Research & Reviews  1,173 results

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
https://clinicaltrials.gov/ct2/show/NCT04578834

May 19th, 2022 - This trial is a multicenter, randomized, double-blind, placebo controlled parallel group study. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing disease progression ...

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Pa...
https://doi.org/10.1001/jama.2022.5368
JAMA Lv J, Wong MG et. al.

May 18th, 2022 - The effect of glucocorticoids on major kidney outcomes and adverse events in IgA nephropathy has been uncertain. To evaluate the efficacy and adverse effects of methylprednisolone in patients with IgA nephropathy at high risk of kidney function de...

Oral Glucocorticoids for IgA Nephropathy.
https://doi.org/10.1001/jama.2022.4638
JAMA Campbell KN

May 18th, 2022 - Oral Glucocorticoids for IgA Nephropathy.|2022|Campbell KN,|

Renal Interstitial Inflammation Predicts Nephropathy Progression in IgA Nephropathy: A ...
https://doi.org/10.1159/000524585
American Journal of Nephrology; Zhu B, Liu WH et. al.

May 17th, 2022 - Renal interstitial inflammation often presents in immunoglobulin A nephropathy (IgAN), but its predictive role in kidney disease progression remains controversial. This retrospective two-center cohort study included 1,420 adult IgAN patients betwe...

Multi-organ involvement and intratubular calcium phosphate deposition in the kidney bio...
https://doi.org/10.1007/s40519-022-01406-6 10.1016/S2215-0366(15)00356-9 10.1309/2Y7X-YDXK-006B-XLT2 10.1258/acb.2011.011185 10.3390/ijms20112712 10.1016/j.kint.2018.02.030
Eating and Weight Disorders : EWD; Suarez GMG, Merino-Ribas A et. al.

May 14th, 2022 - Anorexia nervosa is frequently associated with alcohol use disorder. Both of them may adversely affect almost every body system, leading to worse clinical outcomes and high mortality risk. Nonetheless, there is little evidence interrelating anorex...

see more →

Guidelines  3 results

A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.
https://doi.org/10.1007/s10157-021-02095-8
Clinical and Experimental Nephrology; Suzuki H, Kikuchi M et. al.

Sep 27th, 2021 - A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.|2021|Suzuki H,Kikuchi M,Koike K,Komatsu H,Matsuzaki K,|diagnosis,therapy,

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Evidence-based clinical practice guidelines for IgA nephropathy 2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956709
Clinical and Experimental Nephrology; Yuzawa Y, Yamamoto R et. al.

Apr 21st, 2016 - Evidence-based clinical practice guidelines for IgA nephropathy 2014.|2016|Yuzawa Y,Yamamoto R,Takahashi K,Katafuchi R,Tomita M,|diagnosis,etiology,therapy,

see more →

Clinicaltrials.gov  32 results

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
https://clinicaltrials.gov/ct2/show/NCT04578834

May 19th, 2022 - This trial is a multicenter, randomized, double-blind, placebo controlled parallel group study. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing disease progression ...

Atacicept in Subjects With IgA Nephropathy
https://clinicaltrials.gov/ct2/show/NCT04716231

May 2nd, 2022 - The study will assess multiple doses of atacicept vs. placebo on impact of renal function as measured by proteinuria. Safety, eGFR, serum immunoglobulins and gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 36wk doubl...

Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection
https://clinicaltrials.gov/ct2/show/NCT05320133

Apr 26th, 2022 - This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for eradicating Helicobacter pyl...

Registry of IgA Nephropathy in Chinese Children
https://clinicaltrials.gov/ct2/show/NCT03015974

Apr 22nd, 2022 - A total of 1200 patients diagnosed as primary IgA nephropathy with nephrotic proteinuria will be enrolled among 25 pediatric nephrology medical centers nationwide, according to the following protocol. Establishment of registration database online....

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
https://clinicaltrials.gov/ct2/show/NCT04123613

Mar 31st, 2022 - This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90 Participants in three cohorts. Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropa...

see more →

News  28 results

FDA OKs First Proteinuria Drug for IgA Nephropathy
https://www.medpagetoday.com/nephrology/generalnephrology/96235

Dec 16th, 2021 - The FDA granted accelerated approval for the first drug to reduce proteinuria in primary immunoglobulin A (IgA) nephropathy, the agency announced on Wednesday. The delayed released budesonide (Tarpeyo) capsules are indicated to lower increased pro...

'Strong Evidence' Oral Steroids Slow IgA Nephropathy Progression
https://www.medscape.com/viewarticle/962639

Nov 10th, 2021 - Daily treatment of patients with IgA nephropathy with an oral glucocorticoid, methylprednisolone, led to significant reductions in the rate of kidney failure and a composite tally of adverse incident renal outcomes in a multicenter, randomized tri...

Complement Inhibitor Shows Early Promise in IgA Nephropathy
https://www.medscape.com/viewarticle/952739

Jun 9th, 2021 - A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first targeted therapy for the treatment of IgA nephrop...

New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
https://www.medscape.com/viewarticle/949579

Apr 20th, 2021 - Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the development of end-stage renal disease for patients with immunoglobu...

Rash on legs and abdomen
https://www.mdedge.com/familymedicine/article/215177/dermatology/rash-legs-and-abdomen?channel=114
MDedge Family Medicine;

Jan 16th, 2020 - The rash was consistent with nonblanching purpura. Two punch biopsies were performed for hematoxylin and eosin stain and direct immunofluorescence, which were consistent with IgA mediated small vessel vasculitis, or Henoch-Schoenlein purpura.

see more →

Patient Education  4 results see all →